Journal article
TMOD-02. IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA
Abstract
Glioblastoma (GBM) is a very aggressive and invasive tumor that relapses within nine months of diagnosis and remains incurable despite advances in multimodal therapy including surgical resection, chemotherapy and radiation. Poor patient outcome has been linked to both marker expression of brain tumor initiating cells (BTICs) and intratumoral heterogeneity (ITH), which have been associated with treatment resistance and tumor recurrence. ITH can …
Authors
Yelle N; Chokshi C; Vora P; Venugopal C; Singh S
Journal
Neuro-Oncology, Vol. 19, No. suppl_6, pp. vi254–vi254
Publisher
Oxford University Press (OUP)
Publication Date
November 6, 2017
DOI
10.1093/neuonc/nox168.1041
ISSN
1522-8517